Skip to main content
. Author manuscript; available in PMC: 2013 Oct 1.
Published in final edited form as: Arthritis Rheum. 2012 Oct;64(10):3111–3118. doi: 10.1002/art.34560

Figure 5.

Figure 5

Loss of CD19 with RTX treatment is not due to cell death. A, Flow cytometry histogram of PBMCs without and with RTX (gating on lymphocyte population based on forward and side scatter properties) showing representative leftward shift of CD19 count into the negative population. B, CD19 and CD20 mRNA message from PBMC does not change with addition of RTX. C, Viability dye, propidium iodide, indicates that there is no increase in cell death with addition of RTX despite large decline in CD19 count. Ethanol treated cells were >90% positive for propidium iodide. D, While surface staining supports decrease in CD19 count, intracellular staining indicates that B cells are not lost with addition of RTX. All graphs represent a 30 minute RTX incubation. Bar graphs represent the mean of at least three separate experiments; error bars represent standard error of the mean.